Paid Clinical Trials and Focus Groups by Location |
|
|
|
Conditions: Idiopathic Pulmonary Fibrosis; Familial Pulmonary Fibrosis; Idiopathic Interstitial Pneumonia; Familial Interstitial Pneumonia
Intervention:
Sponsors: National Jewish Health; Duke University; Vanderbilt University; Landspitali University Hospital
Recruiting - verified February 2010
Conditions: Indolent Non-Hodgkin's Lymphoma; Chronic Lymphocytic Leukemia
Interventions: Drug: CAL-101; Drug: Rituximab; Drug: Bendamustine
Sponsor: Calistoga Pharmaceuticals, Inc.
Not yet recruiting - verified March 2010
Condition: Pain
Interventions: Drug: Bupivacaine; Other: Normal Saline
Sponsor: Vanderbilt University
Not yet recruiting - verified March 2010
Condition: Multiple Myeloma
Intervention: Drug: AZD6244 hydrogen sulfate capsules
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Obesity; Bariatric Surgery; Morbid Obesity; Diabetes Mellitus Type 2; Diet Therapy
Interventions: Procedure: Roux-en-Y Gastric Bypass; Behavioral: Caloric Restriction
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified February 2010
Condition: Squamous Cell Lung Cancer
Interventions: Drug: gemcitabine/carboplatin; Drug: gemcitabine/carboplatin plus BSI-201
Sponsors: BiPar Sciences; Sanofi-Aventis
Recruiting - verified March 2010
Conditions: Cancer Survivor; Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Neuroblastoma; Testicular Germ Cell Tumor
Interventions: Genetic: DNA analysis; Genetic: polymerase chain reaction; Other: flow cytometry; Other: laboratory biomarker analysis
Sponsors: Vanderbilt-Ingram Cancer Center; National Cancer Institute (NCI)
Recruiting - verified February 2010
Condition: Obesity
Interventions: Behavioral: Social network building intervention; Behavioral: Home visit
Sponsors: Vanderbilt University; American Heart Association
Not yet recruiting - verified March 2010
Condition: Distal Subungual Onychomycosis
Interventions: Drug: Terbinafine Hydrochloride; Other: Purified Water
Sponsor: Nitric BioTherapeutics, Inc
Not yet recruiting - verified March 2010
Conditions: Arrhythmia; Bradycardia
Intervention:
Sponsor: Medtronic Cardiac Rhythm Disease Management
Recruiting - verified February 2010
Conditions: Arrhythmia; Heart Failure
Intervention:
Sponsor: Medtronic Cardiac Rhythm Disease Management
Recruiting - verified February 2010
Conditions: Arrhythmia; Heart Failure
Intervention:
Sponsor: Medtronic Cardiac Rhythm Disease Management
Recruiting - verified February 2010
Condition: Chronic Urticaria
Interventions: Drug: Placebo; Drug: Hydroxychloroquine
Sponsor: Vanderbilt University
Not yet recruiting - verified February 2010
Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: Placebo; Drug: Tiotropium
Sponsors: Boehringer Ingelheim Pharmaceuticals; Pfizer
Recruiting - verified March 2010
Condition: Advanced Malignancies
Intervention: Drug: INCB028060
Sponsors: Incyte Corporation; Novartis Pharmaceuticals
Recruiting - verified February 2010
Condition: Idiopathic Pulmonary Fibrosis
Intervention:
Sponsors: University of Michigan; National Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health (info added by University of Michigan Data Coordinating Center)
Recruiting - verified November 2009
Condition: Urinary Incontinence
Intervention: Device: Athena Pelvic Muscle Trainer
Sponsor: Athena Feminine Technologies, Inc.
Recruiting - verified March 2010
Condition: Acute Renal Failure
Intervention: Device: Selective cytopheretic device (SCD)
Sponsors: CytoPherx, Inc; Harvard Clinical Research Institute; Medtox
Recruiting - verified February 2010
Conditions: Hyperphosphatemia; End-Stage Renal Disease
Intervention: Drug: ferric citrate
Sponsor: Keryx Biopharmaceuticals
Not yet recruiting - verified February 2010
Condition: Head Lice
Interventions: Drug: 0.5% Ivermectin Cream; Drug: Placebo control
Sponsor: Topaz Pharmaceuticals Inc
Recruiting - verified February 2010
Condition: Sarcoidosis
Intervention: Drug: levaquin, ethambutol, azithromycin, rifampin
Sponsor: Vanderbilt University
Recruiting - verified February 2010
Condition: Respiratory Syncytial Virus Infections
Interventions: Drug: ALN-RSV01; Drug: Normal Saline
Sponsor: Alnylam Pharmaceuticals
Recruiting - verified March 2010
Condition: Influenza
Intervention: Drug: Peramivir
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting - verified January 2010
Condition: Hepatitis C, Chronic
Interventions: Drug: RO5024048; Drug: peginterferon alfa-2a [Pegasys]; Drug: Ribavirin [Copegus]
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Lung Transplantation
Intervention: Drug: Myfortic
Sponsors: Vanderbilt University; Novartis Pharmaceuticals
Recruiting - verified February 2010
Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: aclidinium bromide; Drug: aclidinium bromide
Sponsors: Forest Laboratories; Almirall, S.A.
Recruiting - verified February 2010
Conditions: Breast Cancer; Breast Neoplasms
Interventions: Drug: XL147; Biological: trastuzumab; Drug: paclitaxel
Sponsor: Exelixis
Recruiting - verified February 2010
Condition: Thrombocytopenia in Pediatric Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
Intervention: Biological: Romiplostim
Sponsor: Amgen
Recruiting - verified March 2010
Conditions: Advanced Hepatocellular Carcinoma; Liver Cancer; Hepatic Cancer; Liver Neoplasms
Interventions: Drug: CS-1008; Drug: sorafenib
Sponsor: Daiichi Sankyo Inc.
Recruiting - verified March 2010
Condition: Human Papillomavirus
Intervention:
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting - verified March 2010
Condition: Extensive-Stage Small Cell Lung Cancer
Interventions: Drug: Amrubicin; Drug: Carboplatin; Drug: Pegfilgrastim
Sponsors: Sarah Cannon Research Institute; Celgene Corporation
Recruiting - verified March 2010
Condition: WT1-positive Acute Myeloid Leukemia
Intervention: Biological: GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK2130579A
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Condition: HIV Infections
Intervention:
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified December 2009
Condition: Non Small Cell Lung Cancer
Interventions: Drug: Pazopanib; Drug: Erlotinib
Sponsors: Sarah Cannon Research Institute; GlaxoSmithKline; OSI Pharmaceuticals
Recruiting - verified March 2010
Conditions: Cancer; Melanoma
Intervention: Drug: GSK1120212 Treatment
Sponsor: GlaxoSmithKline
Recruiting - verified February 2010
Condition: Hodgkin Lymphoma
Intervention: Drug: Everolimus (RAD001)
Sponsor: Novartis
Recruiting - verified March 2010
Condition: Hepatitis C, Chronic
Interventions: Drug: Boceprevir (SCH 503034); Drug: erythropoietin; Biological: Peginterferon alfa-2b (SCH 54031); Drug: Ribavirin (SCH 18908)
Sponsor: Schering-Plough
Recruiting - verified March 2010
Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: FF/GW642444 Inhalation Powder; Drug: GW642444 Inhalation Powder
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Condition: Acne Vulgaris
Interventions: Drug: Tazarotene foam; Drug: Vehicle Foam
Sponsor: Stiefel, a GSK Company
Recruiting - verified February 2010
Condition: Asthma
Interventions: Drug: AMG 853; Drug: AMG 853; Drug: AMG 853; Drug: AMG 853; Drug: Placebo
Sponsor: Amgen
Recruiting - verified March 2010
Conditions: Carcinoma, Renal Cell; Lymphoma, Non-Hodgkin
Intervention: Drug: SGN-75
Sponsor: Seattle Genetics, Inc.
Recruiting - verified February 2010
Condition: Sarcoma
Interventions: Biological: bevacizumab; Biological: filgrastim; Biological: pegfilgrastim; Drug: docetaxel; Drug: gemcitabine hydrochloride; Other: placebo
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Malignant Melanoma
Interventions: Drug: RO5185426; Drug: dacarbazine
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Neoplasms
Intervention: Drug: BAY79-4620
Sponsor: Bayer
Recruiting - verified March 2010
Condition: Onychomycosis
Interventions: Drug: IDP-108; Drug: Vehicle
Sponsor: Dow Pharmaceutical Sciences
Recruiting - verified March 2010
Condition: Melanoma
Interventions: Drug: Tasisulam; Drug: Paclitaxel
Sponsor: Eli Lilly and Company
Recruiting - verified March 2010
Conditions: Lymphoma; Lymphoproliferative Disorder
Interventions: Other: biologic sample preservation procedure; Other: informational intervention
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Sexual Dysfunctions, Psychological
Interventions: Drug: flibanserin; Drug: placebo; Drug: placebo
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Condition: Sexual Dysfunctions, Psychological
Interventions: Drug: Flibanserin; Drug: Placebo
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Condition: Psoriasis
Interventions: Drug: Etanercept ONLY; Drug: Methotrexate and Etanercept
Sponsors: Amgen; Immunex Corporation
Recruiting - verified March 2010
Conditions: Acute Lung Injury (ALI); Acute Respiratory Distress Syndrome (ARDS)
Interventions: Drug: SB-681323 Intravenous 7.5mg; Drug: SB-681323 Intravenous 3mg; Drug: SB-681323 Intravenous 7.5 mg; Drug: SB-681323 Intravenous 10mg; Other: Placebo
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Lymphoproliferative Disorder; Methemoglobinemia; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Nonmalignant Neoplasm
Interventions: Drug: chemotherapy; Drug: dapsone; Other: medical chart review; Procedure: assessment of therapy complications
Sponsors: Vanderbilt-Ingram Cancer Center; National Cancer Institute (NCI)
Recruiting - verified December 2009
Conditions: Advanced Solid Tumors; Multiple Myeloma
Intervention: Biological: ACE-041
Sponsor: Acceleron Pharma, Inc.
Recruiting - verified February 2010
Condition: Influenza
Intervention: Biological: Inactivated H1N1 Vaccine
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified November 2009
Condition: Multiple Myeloma
Intervention: Drug: IMGN901
Sponsor: ImmunoGen, Inc.
Recruiting - verified March 2010
Condition: Castrate-Resistant Prostate Cancer
Intervention: Drug: Lenalidomide (CC-5013) 10mg, 15mg, 20mg, 25mg and their respective matching placebo capsules for oral administration
Sponsor: Celgene Corporation
Recruiting - verified March 2010
Condition: HIV Infections
Interventions: Behavioral: Enhanced nursing telephone support; Behavioral: Standard care
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting - verified October 2009
Condition: Lung Cancer
Intervention: Drug: bendamustine hydrochloride
Sponsors: Vanderbilt-Ingram Cancer Center; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Lung Cancer
Interventions: Biological: cetuximab; Biological: cixutumumab; Drug: carboplatin; Drug: paclitaxel
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Hepatitis; Hepatitis C
Interventions: Drug: Filibuvir; Drug: Filibuvir; Drug: Placebo
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Thyroid Neoplasm
Interventions: Drug: Nexavar (Sorafenib, BAY43-9006); Drug: Placebo
Sponsors: Bayer; Onyx Pharmaceuticals
Recruiting - verified March 2010
Condition: Haemophilia A
Interventions: Drug: recombinant factor VIII (N8); Drug: recombinant factor VIII (N8)
Sponsor: Novo Nordisk
Recruiting - verified March 2010
Condition: Castration-Resistant Prostate Cancer
Interventions: Drug: MDV3100; Drug: Placebo
Sponsor: Medivation, Inc.
Recruiting - verified March 2010
Condition: Coronary Artery Disease
Interventions: Drug: Placebo & Aspirin; Drug: Clopidogrel & Aspirin, Prasugrel & Aspirin
Sponsors: Harvard Clinical Research Institute; Abbott; Boston Scientific Corporation; Bristol-Myers Squibb; Sanofi-Synthelabo; Cordis Corporation; Eli Lilly and Company; Daiichi Sankyo Inc.; Medtronic
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Other: Side-effect questionnaires; Other: research blood samples
Sponsors: University of Chicago; Translational Breast Cancer Reserach Consortium; National Institutes of Health (NIH)
Recruiting - verified February 2010
Condition: Hepatitis C
Interventions: Drug: TMC435 /Peg IFNa2A/Ribavirin TMC435 placebo; Drug: TMC435 /Peg IFNa2A/Ribavirin TMC435 placebo; Drug: TMC435 /Peg IFNa2A/Ribavirin; Drug: TMC435 /Peg IFNa2A/Ribavirin; Drug: TMC435 /Peg IFNa2A/Ribavirin TMC435 placebo; Drug: TMC435 /Peg IFNa2A/Ribavirin TMC435 placebo; Drug: TMC435 placebo /Peg IFNa2A/Ribavirin
Sponsor: Tibotec Pharmaceuticals, Ireland
Recruiting - verified February 2010
Condition: Renal Cell Carcinoma
Intervention: Drug: Lenalidomide (CC-5013) in combination with sunitinib
Sponsor: Celgene Corporation
Recruiting - verified February 2010
Condition: Severe Nodular Acne
Intervention: Drug: CIP-Isotretinoin and Isotretinoin
Sponsor: Cipher Pharmaceuticals Inc.
Recruiting - verified February 2010
Condition: Total Elbow Arthroplasty
Intervention: Procedure: Total elbow replacement arthroplasty
Sponsor: Vanderbilt University
Recruiting - verified March 2010
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: glimepiride; Drug: JNJ-28431754
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified February 2010
Conditions: Pain; Neuralgia, Postherpetic; Neuralgia; Mononeuropathies
Interventions: Drug: JNJ-42160443; Drug: Placebo
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified February 2010
Condition: Cancer
Interventions: Genetic: polymorphism analysis; Other: laboratory biomarker analysis
Sponsors: Vanderbilt-Ingram Cancer Center; National Cancer Institute (NCI)
Recruiting - verified June 2009
Condition: Idiopathic Pulmonary Fibrosis
Interventions: Drug: warfarin; Drug: placebo
Sponsors: National Heart, Lung, and Blood Institute (NHLBI); Duke University
Recruiting - verified February 2010
Condition: Cancer
Interventions: Genetic: DNA analysis; Genetic: polymorphism analysis; Other: laboratory biomarker analysis; Other: medical chart review; Other: questionnaire administration; Procedure: assessment of therapy complications; Procedure: evaluation of cancer risk factors
Sponsors: Vanderbilt-Ingram Cancer Center; National Cancer Institute (NCI)
Recruiting - verified April 2009
Conditions: Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: cisplatin; Drug: paclitaxel
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Degenerative Disc Disease With or Without Stenosis
Intervention: Device: chronOS strip
Sponsor: Synthes Spine
Recruiting - verified March 2010
Condition: Endometrial Cancer
Interventions: Drug: carboplatin; Drug: cisplatin; Drug: paclitaxel
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Breast Cancer
Intervention:
Sponsors: Memorial Sloan-Kettering Cancer Center; University of Chicago; Dana-Farber Cancer Institute; Georgetown University; Johns Hopkins University; M.D. Anderson Cancer Center; University of Alabama at Birmingham; University of California, San Francisco; University of North Carolina; Duke University; Vanderbilt-Ingram Cancer Center; The Indiana University Simon Cancer Center; Mayo Clinic; University of Pittsburgh; University of Michigan Health System
Recruiting - verified March 2010
Condition: Tumors
Intervention: Drug: PKI-587
Sponsor: Wyeth
Recruiting - verified March 2010
Conditions: Solid Tumors; Cancer
Interventions: Drug: XL184; Drug: Placebo; Drug: XL184
Sponsor: Exelixis
Recruiting - verified February 2010
Condition: Macular Edema Secondary to Central Retinal Vein Occlusion
Interventions: Biological: VEGF Trap-Eye 2.0mg; Drug: Sham
Sponsors: Regeneron Pharmaceuticals; Bayer
Recruiting - verified February 2010
Condition: Oral Mucositis
Interventions: Biological: AG013; Biological: AG013; Biological: AG013; Other: Placebo; Other: Placebo; Other: Placebo
Sponsor: ActoGeniX N.V.
Recruiting - verified February 2010
Condition: Schizophrenia
Interventions: Drug: oral risperidone; Drug: paliperidone palmitate
Sponsor: Ortho-McNeil Janssen Scientific Affairs, LLC
Recruiting - verified February 2010
Condition: Epilepsy
Interventions: Drug: Lacosamide; Drug: Lacosamide; Drug: Lacosamide
Sponsor: UCB, Inc.
Recruiting - verified February 2010
Condition: Non-Germinal B-Cell-like (GCB) Diffuse Large B-cell Lymphoma (DLBCL)
Interventions: Drug: Vc-RCHOP; Drug: RCHOP
Sponsor: Millennium Pharmaceuticals, Inc.
Recruiting - verified February 2010
Condition: Carcinoma, Non-Small-Cell Lung
Intervention: Drug: PF-02341066
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Heart Failure
Intervention:
Sponsor: Medtronic Cardiac Rhythm Disease Management
Recruiting - verified March 2010
Condition: Attention Deficit Disorder With Hyperactivity
Interventions: Drug: Placebo; Drug: OROS MPH
Sponsor: Ortho-McNeil Janssen Scientific Affairs, LLC
Recruiting - verified February 2010
Condition: Rheumatoid Arthritis
Interventions: Drug: Abatacept; Drug: Adalimumab
Sponsor: Bristol-Myers Squibb
Recruiting - verified December 2009
Condition: Adrenocortical Carcinoma (ACC)
Interventions: Drug: OSI-906; Other: Placebo
Sponsor: OSI Pharmaceuticals
Recruiting - verified August 2009
Conditions: Chordoma; Desmoid Tumor; Sarcoma
Interventions: Genetic: reverse transcriptase-polymerase chain reaction; Other: biologic sample preservation procedure; Other: laboratory biomarker analysis
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Advanced Non-hematologic Malignancies
Intervention: Drug: PF-04605412
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Pneumococcal Conjugate Vaccine
Intervention: Biological: 13vPnC
Sponsor: Wyeth
Recruiting - verified March 2010
Conditions: Advanced Breast Cancer; Breast Cancer
Interventions: Drug: Neratinib + Paclitaxel; Drug: Trastuzumab + Paclitaxel
Sponsor: Wyeth
Recruiting - verified March 2010
Condition: Metastatic Breast Cancer
Interventions: Drug: Everolimus; Drug: Bevacizumab; Drug: Paclitaxel; Drug: Placebo; Drug: Bevacizumab; Drug: Paclitaxel
Sponsors: Sarah Cannon Research Institute; Novartis
Recruiting - verified January 2010
Condition: Variola Major (Smallpox)
Interventions: Biological: IMVAMUNE® (liquid, intradermal); Biological: IMVAMUNE® (lyophilized); Biological: IMVAMUNE® (liquid, subcutaneous)
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified January 2010
Condition: Overactive Bladder
Interventions: Drug: Fesoterodine; Drug: Placebo
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Influenza
Interventions: Biological: A/Anhui/05; Biological: MF-59; Drug: Placebo
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting - verified December 2009
Condition: Colorectal Cancer
Intervention: Drug: olaparib
Sponsors: AstraZeneca; Aptium Oncology Gastrointestinal Cancer Consortium
Recruiting - verified February 2010
Conditions: Atrial Fibrillation; Arrhythmia; Stroke Prevention; Mortality
Interventions: Device: Left atrial ablation; Drug: Rate or Rhythm Control Therapy
Sponsors: Mayo Clinic; National Heart, Lung, and Blood Institute (NHLBI); Duke University; St. Jude Medical; Biosense Webster, Inc.
Recruiting - verified February 2010
Condition: Hepatocellular Carcinoma
Interventions: Drug: Brivanib; Drug: Brivanib Placebo
Sponsor: Bristol-Myers Squibb
Recruiting - verified November 2009
Conditions: Breast Cancer; Chronic Myeloproliferative Disorders; Gestational Trophoblastic Tumor; Graft Versus Host Disease; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Neuroblastoma; Ovarian Cancer; Testicular Germ Cell Tumor
Interventions: Genetic: gene expression analysis; Genetic: microarray analysis; Genetic: polymorphism analysis; Genetic: proteomic profiling; Other: flow cytometry; Other: immunologic technique; Other: laboratory biomarker analysis; Procedure: biopsy
Sponsors: Vanderbilt-Ingram Cancer Center; National Cancer Institute (NCI)
Recruiting - verified October 2008
Condition: Neuroblastoma
Interventions: Genetic: loss of heterozygosity analysis; Other: cytology specimen collection procedure; Procedure: biopsy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Cancer
Intervention: Other: biologic sample preservation procedure
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Leukemia; Neoplasm of Uncertain Malignant Potential; Unspecified Childhood Solid Tumor, Protocol Specific
Intervention: Other: cytology specimen collection procedure
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Kidney Cancer; Nonneoplastic Condition
Interventions: Genetic: loss of heterozygosity analysis; Genetic: polymerase chain reaction; Genetic: polymorphism analysis; Other: immunohistochemistry staining method; Procedure: computed tomography; Procedure: magnetic resonance imaging
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer
Intervention: Other: laboratory biomarker analysis
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Leukemia; Lymphoma
Intervention: Other: biologic sample preservation procedure
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Leukemia; Lymphoma
Intervention: Other: biologic sample preservation procedure
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Sarcoma
Intervention: Other: biologic sample preservation procedure
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Sarcoma
Interventions: Other: biologic sample preservation procedure; Other: medical chart review
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Prostate Cancer
Intervention: Drug: Sipuleucel-T
Sponsor: Dendreon
Recruiting - verified March 2010
Condition: Rheumatoid Arthritis
Interventions: Drug: tocilizumab [RoActemra]; Drug: tocilizumab [RoActemra]; Drug: Nonbiologic DMARDs of investigator's choice
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Breast Cancer
Interventions: Drug: bevacizumab; Drug: docetaxel; Drug: doxorubicin; Drug: cyclophosphamide; Drug: cyclophosphamide; Drug: pegfilgrastim
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); Genentech; US Oncology Research
Recruiting - verified March 2010
Condition: Non Small Cell Lung Cancer
Interventions: Drug: Pemetrexed; Drug: Bevacizumab; Drug: Carboplatin
Sponsors: Sarah Cannon Research Institute; Genentech
Recruiting - verified January 2010
Condition: Endometrial Cancer
Interventions: Drug: Ixabepilone; Drug: Doxorubicin; Drug: Paclitaxel
Sponsor: Bristol-Myers Squibb
Recruiting - verified March 2010
Conditions: Breast Cancer; Cardiac Toxicity; Cardiovascular Complications
Interventions: Biological: trastuzumab; Drug: doxorubicin hydrochloride; Genetic: polymorphism analysis; Other: laboratory biomarker analysis; Other: questionnaire administration; Procedure: assessment of therapy complications; Procedure: magnetic resonance imaging
Sponsors: Vanderbilt-Ingram Cancer Center; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Cancer; Melanoma; Solid Tumor Cancer
Interventions: Drug: Midazolam; Drug: GSK2118436; Drug: GSK2118436
Sponsor: GlaxoSmithKline
Recruiting - verified February 2010
Conditions: Idiopathic Pulmonary Fibrosis; Pulmonary Hypertension
Intervention: Drug: Ambrisentan or placebo
Sponsor: Gilead Sciences
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Drug: neratinib; Other: placebo
Sponsor: Wyeth
Recruiting - verified March 2010
Condition: Myocardial Infarction
Interventions: Drug: Prochymal®; Drug: Placebo
Sponsor: Osiris Therapeutics
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Drug: Everolimus; Drug: Placebo
Sponsor: Novartis Pharmaceuticals
Recruiting - verified February 2010
Condition: Occult Primary
Interventions: Drug: belinostat, carboplatin, paclitaxel; Drug: carboplatin, paclitaxel
Sponsor: TopoTarget A/S
Recruiting - verified March 2010
Condition: Hepatitis C, Chronic
Interventions: Drug: RO5024048; Drug: RO5024048; Drug: RO5024048; Drug: Pegasys; Drug: Pegasys; Drug: Copegus; Drug: Copegus
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Heart Failure
Intervention:
Sponsor: Medtronic Cardiac Rhythm Disease Management
Recruiting - verified February 2010
Condition: Diabetic Neuropathies
Interventions: Drug: Carisbamate 800 mg/d; Drug: Pregabalin 300 mg/d; Drug: Placebo; Drug: Carisbamate 1,200 mg/d
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified February 2010
Conditions: Actinic Keratoses; Skin Neoplasms
Interventions: Drug: Aminolevulinic Acid; Other: Vehicle
Sponsor: DUSA Pharmaceuticals, Inc.
Recruiting - verified March 2010
Condition: Epilepsy With Simple or Complex Partial Onset Seizures
Interventions: Drug: Eslicarbazepine acetate; Drug: Eslicarbazepine acetate
Sponsor: Sepracor, Inc.
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Drug: Everolimus, Exemestane; Drug: Placebo, Exemestane
Sponsor: Novartis Pharmaceuticals
Recruiting - verified March 2010
Conditions: Blast Phase Philadelphia Chromosomes Positive (Ph+) Chronic Myelogenous Leukemia; Philadelphia Chromosome Positive (Ph+) Acute Lymphocytic Leukemia
Intervention: Other: Comparator: Biomarker evaluation
Sponsor: Merck
Recruiting - verified March 2010
Condition: Non-small Cell Lung Cancer
Interventions: Drug: erlotinib HCl; Drug: MetMAb; Drug: placebo
Sponsor: Genentech
Recruiting - verified March 2010
Conditions: Herpes Zoster; HIV Infections
Interventions: Biological: Zoster Vaccine Live; Biological: Placebo
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); Adult AIDS Clinical Trials Group; Merck
Recruiting - verified May 2009
Condition: Bipolar Depression
Interventions: Drug: cariprazine; Drug: cariprazine; Drug: placebo
Sponsors: Forest Laboratories; Gedeon Richter Ltd.
Recruiting - verified March 2010
Condition: Colorectal Cancer (CRC)
Interventions: Drug: Irinotecan; Drug: 5-Fluorouracil (bolus); Drug: 5-Fluorouracil (infusional); Drug: Leucovorin calcium; Drug: CT-322; Drug: Bevacizumab; Drug: Bevacizumab Placebo (saline solution)
Sponsor: Bristol-Myers Squibb
Recruiting - verified January 2010
Conditions: Stress Urinary Incontinence; Cell Therapy
Intervention: Biological: autologous muscle cell injection
Sponsor: Cook
Recruiting - verified February 2010
Condition: Ovarian Cancer
Interventions: Drug: MORAb-003 (farletuzumab); Drug: MORAb-003 (farletuzumab); Drug: 0.9% Saline
Sponsor: Morphotek
Recruiting - verified October 2009
Condition: Haemophilia A
Interventions: Drug: recombinant factor VIII (N8); Procedure: Blood drawn for laboratory testing
Sponsor: Novo Nordisk
Recruiting - verified March 2010
Condition: Advanced Solid Tumors
Interventions: Drug: ARRY-334543; Drug: Docetaxel
Sponsor: Array BioPharma
Recruiting - verified February 2010
Conditions: Adrenocortical Carcinoma; Kidney Cancer; Liver Cancer; Neuroblastoma; Retinoblastoma; Sarcoma
Interventions: Biological: cixutumumab; Other: laboratory biomarker analysis
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Acute Coronary Syndrome
Interventions: Drug: Apixaban; Drug: Placebo
Sponsors: Bristol-Myers Squibb; Pfizer; Duke University
Recruiting - verified October 2009
Condition: Advanced Solid Tumors
Intervention: Biological: TAK-701
Sponsor: Millennium Pharmaceuticals, Inc.
Recruiting - verified March 2010
Condition: Advanced Non-hematologic Malignancies
Intervention: Drug: MLN9708
Sponsor: Millennium Pharmaceuticals, Inc.
Recruiting - verified March 2010
Condition: Carcinoma, Non-small Cell
Intervention: Drug: PF-00299804
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: HIV Infections
Interventions: Biological: Vaccine; Biological: Placebo
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2009
Condition: Postoperative Pain
Interventions: Drug: Oxycodone IR; Drug: Tapentadol IR
Sponsors: Ortho-McNeil Janssen Scientific Affairs, LLC; Grünenthal GmbH
Recruiting - verified February 2010
Condition: HIV Infections
Interventions: Drug: Emtricitabine/tenofovir disoproxil fumarate; Drug: Raltegravir; Drug: Darunavir; Drug: Ritonavir
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); Bristol-Myers Squibb; Gilead Sciences; Merck; Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA
Recruiting - verified June 2009
Condition: Rheumatoid Arthritis
Interventions: Drug: tocilizumab [RoActemra]; Drug: methotrexate; Drug: placebo
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Conditions: Endometrial Cancer; Fatigue; Neurotoxicity
Interventions: Drug: carboplatin; Drug: paclitaxel; Radiation: brachytherapy; Radiation: intensity-modulated radiation therapy; Radiation: radiation therapy
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Cervical Cancer
Interventions: Biological: bevacizumab; Drug: cisplatin; Drug: paclitaxel; Drug: topotecan hydrochloride
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Solid Tumors
Intervention: Drug: Sunitinib
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Resected Stage III Melanoma With Macroscopic Involvement
Interventions: Drug: GSK 2132231A; Drug: Placebo
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Conditions: Cancer; Solid Tumors
Interventions: Drug: Lapatinib in combination with an anti-cancer agent; Drug: Lapatinib; Drug: Lapatinib in combination with an anti-cancer agent as specified by parent protocol
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Sitagliptin phosphate; Drug: Comparator: Placebo
Sponsors: Merck; Duke Clinical Research Institute, Oxford Diabetes Trials Unit
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Biological: bevacizumab; Drug: ixabepilone; Drug: paclitaxel; Drug: paclitaxel albumin-stabilized nanoparticle formulation
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Cancer
Intervention: Drug: PF-04554878
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Gastrointestinal Stromal Tumor (GIST)
Interventions: Drug: Nilotinib (AMN107); Drug: imatinib (STI571)
Sponsor: Novartis Pharmaceuticals
Recruiting - verified February 2010
Condition: Pulmonary Fibrosis
Intervention: Drug: CNTO 888
Sponsor: Centocor, Inc.
Recruiting - verified February 2010
Condition: Crohn's Disease
Interventions: Drug: vedolizumab; Other: Placebo
Sponsor: Millennium Pharmaceuticals, Inc.
Recruiting - verified March 2010
Condition: Ulcerative Colitis
Interventions: Drug: vedolizumab; Other: Placebo
Sponsor: Millennium Pharmaceuticals, Inc.
Recruiting - verified March 2010
Conditions: Carcinoma; Neuroendocrine Tumors
Intervention: Biological: A12
Sponsor: ImClone LLC
Recruiting - verified February 2010
Condition: Hepatitis C, Chronic
Interventions: Drug: peginterferon alfa-2a [Pegasys]; Drug: ribavirin [Copegus]
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Breast Cancer
Interventions: Biological: trastuzumab; Drug: lapatinib ditosylate; Drug: paclitaxel
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Brain and Central Nervous System Tumors; Chemotherapeutic Agent Toxicity; Cognitive/Functional Effects; Neurotoxicity; Psychosocial Effects of Cancer and Its Treatment; Radiation Toxicity; Therapy-related Toxicity
Interventions: Other: questionnaire administration; Procedure: cognitive assessment; Procedure: psychosocial assessment and care; Procedure: quality-of-life assessment
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Crohn's Disease
Intervention: Drug: Ustekinumab; CNTO1275
Sponsor: Centocor, Inc.
Recruiting - verified March 2010
Condition: Prostate Cancer
Interventions: Device: HIFU (Sonablate® 500); Device: Brachytherapy
Sponsor: USHIFU, LLC
Recruiting - verified March 2010
Condition: Idiopathic Pulmonary Fibrosis
Intervention: Drug: ambrisentan or sugar pill
Sponsor: Gilead Sciences
Recruiting - verified March 2010
Condition: Melanoma
Interventions: Biological: OncoVEXGM-CSF; Biological: GM-CSF
Sponsor: BioVex Limited
Recruiting - verified March 2010
Condition: Non-small Cell Lung Cancer
Interventions: Drug: RG1507; Drug: Placebo; Drug: RG1507; Drug: Placebo; Drug: erlotinib [Tarceva]
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Conditions: Chronic Myeloproliferative Disorders; Graft Versus Host Disease; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases
Interventions: Drug: cyclosporine ophthalmic emulsion; Other: placebo
Sponsors: Vanderbilt-Ingram Cancer Center; National Cancer Institute (NCI)
Recruiting - verified July 2009
Condition: Non-small Cell Lung Cancer
Interventions: Drug: ASA404 in combination with docetaxel; Drug: Placebo in combination with docetaxel
Sponsor: Novartis Pharmaceuticals
Recruiting - verified March 2010
Condition: Major Depressive Disorder (MDD)
Intervention: Drug: repeat dose
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Conditions: Renal Dialysis; Hemodialysis
Interventions: Drug: ramipril; Drug: valsartan; Drug: Placebo
Sponsors: Vanderbilt University; National Institutes of Health (NIH)
Recruiting - verified March 2010
Condition: Neoplasms
Intervention: Drug: Comparator: ridaforolimus + dalotuzumab
Sponsors: Merck; Ariad Pharmaceuticals
Recruiting - verified March 2010
Condition: Diabetes Mellitus
Interventions: Drug: Comparison of the effect of aldosterone versus vehicle infusion; Drug: Comparison of the effect of aldosterone versus vehicle infusion
Sponsors: Vanderbilt University; National Heart, Lung, and Blood Institute (NHLBI); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified February 2010
Conditions: Metastatic Castration-resistant Prostrate Cancer (mCRPC); Renal Cell Carcinoma (RCC); Malignant Melanoma (MEL); Non-small Cell Lung Cancer (NSCLC)
Intervention: Biological: MDX-1106
Sponsor: Bristol-Myers Squibb
Recruiting - verified March 2010
Condition: Colorectal Cancer
Interventions: Procedure: therapeutic conventional surgery; Procedure: therapeutic laparoscopic surgery
Sponsors: American College of Surgeons; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Communication Disorders; Developmental Disabilities
Intervention: Behavioral: Milieu Communication Teaching
Sponsors: University of Kansas; National Institute on Deafness and Other Communication Disorders (NIDCD)
Recruiting - verified March 2010
Condition: Mantle Cell Lymphoma
Interventions: Drug: Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone; Drug: Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone
Sponsors: Millennium Pharmaceuticals, Inc.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified February 2010
Condition: Locally Advanced and/or Metastatic Renal Cell Carcinoma
Interventions: Drug: Sunitinib; Drug: Pazopanib
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Condition: Solid Tumor
Intervention: Drug: IMGN388
Sponsor: ImmunoGen, Inc.
Recruiting - verified March 2010
Condition: Hepatitis C
Interventions: Drug: PF-00868554; Drug: PF-00868554; Drug: PF-00868554; Drug: Placebo
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Colorectal Cancer
Interventions: Drug: IMO-2055; Drug: Cetuximab; Drug: FOLFIRI
Sponsor: EMD Serono
Recruiting - verified March 2010
Conditions: Carcinoma, Renal Cell; Adenocarcinoma, Renal Cell; Nephroid Carcinoma; Carcinoma, Hypernephroid
Interventions: Drug: bevacizumab, RAD001(Everolimus); Drug: bevacizumab, interferon alfa-2a
Sponsors: Novartis Pharmaceuticals; Roche Pharma AG
Recruiting - verified March 2010
Condition: Secondary Acute Myeloid Leukemia (Secondary AML, sAML)
Interventions: Drug: Daunorubicin and Cytarabine; Drug: Amonafide and Cytarabine
Sponsor: Antisoma Research
Recruiting - verified March 2010
Condition: Patent Ductus Arteriosus
Intervention: Device: AMPLATZER Duct Occluder II
Sponsor: AGA Medical Corporation
Recruiting - verified March 2010
Condition: Skin Diseases, Infectious
Interventions: Drug: Daptomycin; Drug: Vancomycin, Clindamycin or semi-synthetic Penicillins
Sponsor: Cubist Pharmaceuticals
Recruiting - verified February 2010
Condition: Advanced Colorectal Cancer
Interventions: Drug: ABT-869; Drug: bevacizumab; Drug: oxaliplatin; Drug: folinic acid; Drug: fluorouracil; Drug: ABT-869
Sponsors: Abbott; Genentech
Recruiting - verified January 2010
Condition: Carcinoma, Hepatocellular
Interventions: Drug: sunitinib malate; Drug: sorafenib
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Thyroid Cancer
Interventions: Drug: XL184; Drug: Placebo
Sponsor: Exelixis
Recruiting - verified March 2010
Condition: Lung Cancer
Interventions: Drug: sunitinib malate; Other: placebo
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: B-cell Follicular Lymphoma; B-cell Marginal Zone Lymphoma; Diffuse Large B-cell Lymphoma; B-cell Mantle Cell Lymphoma; B-cell Small Lymphocytic Lymphoma (SLL); B-Cell Chronic Lymphocytic Leukemia (B-CLL); Multiple Myeloma; Waldenstrom's Macroglobulinemia
Intervention: Drug: MLN8237
Sponsor: Millennium Pharmaceuticals, Inc.
Recruiting - verified February 2010
Condition: Solid Tumors and Lymphoma
Intervention: Drug: GSK1120212
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Condition: Non Small Cell Lung Cancer
Interventions: Drug: Pemetrexed; Drug: Cisplatin; Drug: Etoposide; Drug: Cisplatin; Drug: Vinorelbine; Drug: Paclitaxel; Drug: Carboplatin; Radiation: Thoracic Radiation Therapy (TRT); Radiation: Thoracic Radiation Therapy (TRT)
Sponsor: Eli Lilly and Company
Recruiting - verified March 2010
Conditions: Postural Tachycardia Syndrome; Orthostatic Intolerance
Interventions: Drug: Carbidopa; Drug: Placebo
Sponsor: Vanderbilt University
Recruiting - verified March 2010
Condition: Kidney Neoplasms
Interventions: Drug: Axitinib (AG-013736); Drug: Sorafenib
Sponsor: Pfizer
Recruiting - verified March 2010
Conditions: Dyslipidemias; Coronary Heart Disease; Kidney Disease
Interventions: Drug: ABT-335; Drug: Rosuvastatin; Drug: Placebo
Sponsors: Abbott; AstraZeneca
Recruiting - verified February 2010
Condition: Multiple Sclerosis
Interventions: Drug: Teriflunomide (HMR1726); Drug: Placebo
Sponsor: Sanofi-Aventis
Recruiting - verified March 2010
Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Lymphoproliferative Disorder; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Pain; Precancerous Condition; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Other: educational intervention; Other: medical chart review; Other: questionnaire administration; Procedure: pain therapy; Procedure: quality-of-life assessment
Sponsors: Vanderbilt-Ingram Cancer Center; National Cancer Institute (NCI)
Recruiting - verified October 2009
Condition: Leukemia
Interventions: Drug: SC-PEG E. coli L-asparaginase; Drug: cyclophosphamide; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: methotrexate; Drug: pegaspargase; Drug: prednisone; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Breast Cancer; Cognitive/Functional Effects; Fatigue; Psychosocial Effects of Cancer and Its Treatment; Sleep Disorders
Interventions: Procedure: assessment of therapy complications; Procedure: cognitive assessment; Procedure: fatigue assessment and management; Procedure: psychosocial assessment and care
Sponsors: International Breast Cancer Study Group; National Cancer Institute (NCI); Australian New Zealand Breast Cancer Trials Group; Cancer and Leukemia Group B
Recruiting - verified March 2010
Condition: Leukemia
Interventions: Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: midostaurin; Other: placebo
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Pulmonary Fibrosis
Interventions: Drug: Prednisone; Drug: Azathioprine; Drug: N-acetylcysteine (NAC); Drug: Placebo
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified February 2010
Condition: High Risk Stage III Melanoma
Interventions: Drug: ipilimumab; Drug: Placebo
Sponsor: Bristol-Myers Squibb
Recruiting - verified January 2010
Conditions: Neurofibromatosis Type 1; Reading Disabilities
Interventions: Behavioral: Tutoring Program I; Behavioral: Tutoring Program II
Sponsors: Vanderbilt University; National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified February 2010
Condition: Neoplasms
Intervention: Drug: Sorafenib (Nexavar, BAY43-9006)
Sponsors: Bayer; ICON Clinical Research
Recruiting - verified March 2010
Condition: Head and Neck Cancer
Interventions: Biological: IMC-A12; Biological: cetuximab
Sponsor: ImClone LLC
Recruiting - verified March 2010
Condition: Hypoactive Sexual Desire Disorder
Interventions: Drug: testosterone gel; Drug: placebo gel
Sponsor: BioSante Pharmaceuticals
Recruiting - verified February 2010
Condition: Chronic Lymphocytic Leukemia (CLL)
Intervention: Drug: TRU-016 (anti-CD37 protein therapeutic)
Sponsor: Trubion Pharmaceuticals
Recruiting - verified March 2010
Condition: Prostate Cancer
Interventions: Drug: Docetaxel; Drug: ZD4054
Sponsor: AstraZeneca
Recruiting - verified February 2010
Condition: Prostate Cancer
Interventions: Drug: ZD4054; Drug: Luteinising hormone-releasing hormone analogue (LHRHa); Drug: Megace; Drug: Estradiol; Drug: Prednisolone; Drug: Ketoconazole; Drug: Docetaxel
Sponsor: AstraZeneca
Recruiting - verified February 2010
Condition: Hypoactive Sexual Desire Disorder
Interventions: Drug: testosterone gel; Drug: placebo gel
Sponsor: BioSante Pharmaceuticals
Recruiting - verified February 2010
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: lenalidomide; Drug: melphalan; Drug: prednisone; Drug: thalidomide
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: HIV Infections; Sexually Transmitted Diseases
Intervention: Biological: Quadrivalent human papillomavirus vaccine
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Dental and Craniofacial Research (NIDCR)
Recruiting - verified June 2009
Condition: Epilepsy
Intervention: Drug: pregabalin
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Hematologic Neoplasms
Intervention: Drug: SNX-5422
Sponsors: Pfizer; Serenex, Inc.
Recruiting - verified March 2010
Condition: Head and Neck Cancer
Interventions: Biological: bevacizumab; Drug: cisplatin; Drug: docetaxel; Drug: fluorouracil
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Pneumonia; Pneumonia, Bacterial
Interventions: Drug: doripenem; Drug: imipenem/cilastatin
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified February 2010
Condition: Venous Thromboembolism
Interventions: Drug: Xarelto (Rivaroxaban, BAY59-7939); Drug: Enoxaparin
Sponsors: Bayer; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified March 2010
Condition: Neuroendocrine Carcinoma
Interventions: Biological: bevacizumab; Biological: recombinant interferon alfa-2b; Drug: octreotide acetate
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Metastatic Breast Cancer
Interventions: Drug: docetaxel; Drug: pertuzumab; Drug: placebo; Drug: trastuzumab
Sponsors: Genentech; Roche Pharma AG
Recruiting - verified March 2010
Condition: Hemodialysis
Intervention:
Sponsors: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Vanderbilt University; University of Utah
Recruiting - verified March 2010
Condition: Advanced Solid Tumors
Intervention: Drug: PF-03446962
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Leukemia
Interventions: Drug: asparaginase; Drug: cyclophosphamide; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: dexamethasone; Drug: etoposide; Drug: lestaurtinib; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: methylprednisolone; Drug: pegaspargase; Drug: prednisone; Drug: therapeutic hydrocortisone; Drug: vincristine sulfate
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Kidney Disease; Nephropathy; Type 2 Diabetes
Interventions: Drug: losartan; Drug: lisinopril; Drug: losartan
Sponsor: Department of Veterans Affairs
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Drug: Lapatinib; Drug: Trastuzumab; Drug: Endocrine
Sponsors: Baylor Breast Care Center; GlaxoSmithKline
Recruiting - verified February 2010
Conditions: Breast Cancer; Carcinoma of the Breast
Interventions: Drug: Paclitaxel; Drug: Trastuzumab
Sponsors: Dana-Farber Cancer Institute; Brigham and Women's Hospital; Beth Israel Deaconess Medical Center; Massachusetts General Hospital; Genentech
Recruiting - verified March 2010
Conditions: Schizophrenia; Schizoaffective Disorder
Interventions: Drug: long-acting injectable risperidone; Drug: long acting injectable risperidone; Drug: long acting injectable risperidone
Sponsors: Vanderbilt University; Ortho-McNeil Janssen Scientific Affairs, LLC
Recruiting - verified February 2010
Condition: Leukemia
Intervention: Drug: asparaginase-Erwinia
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: HIV Infections
Interventions: Drug: Enfuvirtide; Drug: Raltegravir; Drug: Darunavir; Drug: Tipranavir; Drug: Etravirine; Drug: Maraviroc
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); Adult AIDS Clinical Trials Group
Recruiting - verified April 2009
Conditions: Atherosclerosis; Myocardial Ischemia; Myocardial Infarction
Interventions: Drug: SCH 530348; Drug: Placebo
Sponsors: Schering-Plough; Duke University
Recruiting - verified March 2010
Condition: Metastatic Brain Cancer
Intervention: Drug: GLIADEL
Sponsor: Eisai Inc.
Recruiting - verified March 2010
Condition: Epilepsies, Partial
Interventions: Drug: pregabalin 600 mg/day; Drug: pregabalin 150 mg/day
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Epilepsy
Interventions: Drug: lacosamide; Drug: lacosamide
Sponsor: UCB, Inc.
Recruiting - verified March 2010
Condition: Multiple Myeloma
Interventions: Drug: bortezomib, thalidomide, and dexamethasone (VTD); Drug: bortezomib and dexamethasone (VD); Drug: bortezomib, melphalan and prednisone (VMP)
Sponsor: Millennium Pharmaceuticals, Inc.
Recruiting - verified February 2010
Condition: Cancer
Intervention: Drug: SNX-5422
Sponsors: Pfizer; Serenex, Inc.
Recruiting - verified March 2010
Conditions: Sepsis; Severe Sepsis; Septic Shock
Interventions: Procedure: Early Goal Directed Therapy (EGDT); Procedure: Protocolized Standard Care (PSC); Procedure: Usual Care (UC)
Sponsors: National Institute of General Medical Sciences (NIGMS); University of Pittsburgh
Recruiting - verified September 2008
Condition: Advanced Malignancies
Intervention: Drug: MLN8237
Sponsor: Millennium Pharmaceuticals, Inc.
Recruiting - verified February 2010
Condition: Neuroblastoma
Interventions: Drug: carboplatin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: topotecan hydrochloride
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Lung Neoplasms
Intervention: Drug: Pemetrexed
Sponsor: Eli Lilly and Company
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Biological: Trastuzumab; Drug: Lapatinib
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Condition: Ulcerative Colitis
Interventions: Biological: golimumab, placebo; Biological: Golimumab, placebo; Biological: Placebo
Sponsors: Centocor, Inc.; Schering-Plough
Recruiting - verified February 2010
Condition: Ulcerative Colitis
Interventions: Biological: Golimumab, placebo; Biological: Golimumab, placebo; Biological: Golimumab, placebo; Biological: Placebo
Sponsors: Centocor, Inc.; Schering-Plough
Recruiting - verified February 2010
Condition: Leukemia
Interventions: Genetic: DNA ploidy analysis; Genetic: chromosomal translocation analysis; Genetic: fluorescence in situ hybridization; Genetic: polymorphism analysis; Other: immunologic technique; Other: laboratory biomarker analysis; Procedure: biopsy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Tumor Antigen-positive Non-Small Cell Lung Cancer
Interventions: Biological: GSK1572932A Antigen-Specific Cancer Immunotherapeutic; Biological: Placebo Control
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Condition: Heart Decompensation
Interventions: Drug: Placebo; Drug: Nesiritide
Sponsor: Scios, Inc.
Recruiting - verified February 2010
Condition: Cytomegalovirus Infections
Interventions: Drug: Placebo; Drug: Valganciclovir
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified October 2009
Condition: Colorectal Neoplasms
Interventions: Drug: bevacizumab; Drug: AG-013726; Drug: AG-013736 (axitinib)
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Non-small Cell Lung Cancer
Interventions: Drug: AMG 706; Drug: placebo
Sponsors: Amgen; Takeda Global Research & Development Center, Inc.
Recruiting - verified March 2010
Condition: Cervical Cancer
Interventions: Genetic: microarray analysis; Genetic: mutation analysis; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis; Procedure: lymphadenectomy
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Pulmonary Embolism
Interventions: Drug: Xarelto (Rivaroxaban, BAY59-7939); Drug: Enoxaparin followed by VKA
Sponsors: Bayer; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Biological: bevacizumab; Drug: cyclophosphamide; Drug: paclitaxel; Drug: pegylated liposomal doxorubicin hydrochloride; Other: placebo
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI); North Central Cancer Treatment Group; Cancer and Leukemia Group B
Recruiting - verified March 2010
Conditions: Cognitive/Functional Effects; Leukemia; Long-term Effects Secondary to Cancer Therapy in Children; Neurotoxicity; Psychosocial Effects of Cancer and Its Treatment
Interventions: Genetic: microarray analysis; Genetic: polymorphism analysis; Other: laboratory biomarker analysis; Other: pharmacological study; Procedure: cognitive assessment; Procedure: diffusion tensor imaging; Procedure: management of therapy complications; Procedure: psychosocial assessment and care
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Prostate Cancer
Interventions: Drug: docetaxel; Drug: goserelin; Drug: leuprolide acetate; Procedure: conventional surgery
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI); Eastern Cooperative Oncology Group; NCIC Clinical Trials Group
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Biological: bevacizumab; Drug: capecitabine; Drug: cyclophosphamide; Drug: docetaxel; Drug: doxorubicin hydrochloride; Drug: gemcitabine hydrochloride; Procedure: conventional surgery
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Leukemia
Interventions: Drug: cyclophosphamide; Drug: cytarabine; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: nelarabine; Drug: pegaspargase; Drug: thioguanine; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Interstitial Cystitis
Intervention: Drug: pentosan polysulfate sodium
Sponsor: McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Recruiting - verified February 2010
Condition: Brain and Central Nervous System Tumors
Interventions: Biological: filgrastim; Drug: carboplatin; Drug: cisplatin; Drug: cyclophosphamide; Drug: isotretinoin; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Influenza
Intervention: Drug: oseltamivir (Tamiflu®)
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified February 2010
Condition: Breast Cancer
Intervention: Drug: chemotherapy
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI); Cancer and Leukemia Group B
Recruiting - verified March 2010
Conditions: Graft Versus Host Disease; Leukemia
Interventions: Drug: methotrexate; Drug: sirolimus; Drug: tacrolimus
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Leukemia
Interventions: Biological: filgrastim; Drug: asparaginase; Drug: cyclophosphamide; Drug: cytarabine; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: etoposide phosphate; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: prednisone; Drug: therapeutic hydrocortisone; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Kidney Cancer
Interventions: Biological: bevacizumab; Drug: sorafenib tosylate; Drug: temsirolimus
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Osteoarthritis
Interventions: Drug: Celecoxib; Drug: Any commercially available NSAID with the indication for osteoarthritis
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Leukemia
Interventions: Drug: clofarabine; Drug: cytarabine; Drug: methotrexate; Other: laboratory biomarker analysis
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Leukemia
Interventions: Drug: asparaginase; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: etoposide; Drug: gemtuzumab ozogamicin; Drug: mitoxantrone hydrochloride
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Heart Failure; Anemia; Cardiovascular Disease; Ventricular Dysfunction; Congestive Heart Failure
Interventions: Drug: Darbepoetin alfa; Drug: Placebo
Sponsor: Amgen
Recruiting - verified March 2010
Condition: Sarcoma
Interventions: Biological: dactinomycin; Drug: cyclophosphamide; Drug: irinotecan hydrochloride; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: HIV-1
Intervention: Drug: TMC125
Sponsor: Tibotec Pharmaceuticals, Ireland
Recruiting - verified February 2010
Conditions: Amyotrophic Lateral Sclerosis; ALS
Interventions: Drug: ceftriaxone; Other: placebo
Sponsors: Massachusetts General Hospital; National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified March 2010
Conditions: Arthritis, Rheumatoid; Osteoarthritis
Interventions: Drug: celecoxib; Drug: Ibuprofen; Drug: Naproxen
Sponsors: Pfizer; The Cleveland Clinic
Recruiting - verified March 2010
Condition: Brain and Central Nervous System Tumors
Interventions: Drug: carboplatin; Drug: cisplatin; Drug: cyclophosphamide; Drug: etoposide; Drug: leucovorin calcium; Drug: methotrexate; Drug: thiotepa; Drug: vincristine sulfate
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Kidney Cancer
Interventions: Biological: dactinomycin; Drug: carboplatin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: irinotecan hydrochloride; Drug: vincristine sulfate; Procedure: conventional surgery; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Retinoblastoma
Interventions: Drug: carboplatin; Drug: etoposide; Drug: vincristine sulfate; Other: clinical observation
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Lung Cancer
Interventions: Biological: bevacizumab; Drug: cisplatin; Drug: docetaxel; Drug: gemcitabine hydrochloride; Drug: pemetrexed disodium; Drug: vinorelbine ditartrate
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI); Southwest Oncology Group; Cancer and Leukemia Group B; NCIC Clinical Trials Group; North Central Cancer Treatment Group
Recruiting - verified March 2010
Condition: Kidney Cancer
Interventions: Drug: sorafenib tosylate; Drug: sunitinib malate; Other: placebo
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI); Cancer and Leukemia Group B; Southwest Oncology Group; NCIC Clinical Trials Group
Recruiting - verified March 2010
Conditions: Epilepsy; Epilepsy, Generalized; Epilepsy, Complex Partial; Epilepsies, Partial; Seizures
Interventions: Drug: Diazepam; Drug: Placebo
Sponsor: King Pharmaceuticals Research and Development
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Drug: anastrozole; Drug: chemotherapy; Drug: exemestane; Drug: letrozole; Drug: tamoxifen citrate
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI); Southwest Oncology Group; Cancer and Leukemia Group B; American College of Surgeons; North Central Cancer Treatment Group; NCIC Clinical Trials Group; National Surgical Adjuvant Breast and Bowel Project (NSABP)
Recruiting - verified March 2010
Condition: Prostate Cancer
Interventions: Drug: antiandrogen therapy; Drug: docetaxel
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Hereditary Breast/Ovarian Cancer (brca1, brca2); Osteoporosis; Ovarian Cancer
Interventions: Drug: zoledronic acid; Other: clinical observation
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Pulmonary Hypertension
Interventions: Drug: bosentan; Drug: placebo
Sponsor: Actelion
Recruiting - verified March 2010
Condition: Prostate Cancer
Intervention: Device: Integrated Imaging High Intensity Focused Ultrasound
Sponsor: EDAP TMS S.A.
Recruiting - verified February 2010
Condition: Ischemia
Intervention:
Sponsors: University of South Alabama; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified September 2009
Conditions: Arrhythmia; Bradycardia; Heart Failure; Sinus Tachycardia
Intervention:
Sponsor: Medtronic Cardiac Rhythm Disease Management
Recruiting - verified February 2010
Condition: Colorectal Cancer
Interventions: Biological: bevacizumab; Biological: cetuximab; Drug: fluorouracil; Drug: irinotecan hydrochloride; Drug: leucovorin calcium; Drug: oxaliplatin
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI); Southwest Oncology Group
Recruiting - verified March 2010
Condition: Leukemia
Interventions: Behavioral: compliance monitoring; Drug: mercaptopurine; Drug: methotrexate; Other: study of socioeconomic and demographic variables
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Drug: anastrozole; Drug: exemestane; Drug: letrozole
Sponsors: American College of Surgeons; National Cancer Institute (NCI); Cancer and Leukemia Group B
Recruiting - verified March 2010
Condition: Colorectal Cancer
Interventions: Biological: bevacizumab; Drug: fluorouracil; Drug: leucovorin calcium; Drug: oxaliplatin; Other: clinical observation
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Schizophrenia; Schizoaffective Disorder; Bipolar Disorder; Major Depression
Interventions: Procedure: genetic analysis; Procedure: genetic assay
Sponsor: Vanderbilt University
Recruiting - verified February 2010
Condition: Atrial Fibrillation
Interventions: Drug: Placebo; Drug: Ramipril; Drug: Spironolactone
Sponsors: Vanderbilt University; National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified February 2010
Condition: Sarcoma
Interventions: Biological: PEG-interferon alfa-2b; Drug: cisplatin; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: methotrexate
Sponsors: Children's Oncology Group; National Cancer Institute (NCI); University College London Hospitals
Recruiting - verified March 2010
Condition: Cytomegalovirus Infections
Interventions: Biological: CMV gB vaccine; Drug: Placebo; Biological: MF-59
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified November 2009
Condition: Lymphoma
Interventions: Biological: filgrastim; Biological: rituximab; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: prednisone; Drug: vincristine sulfate
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Lymphoma
Interventions: Drug: CHOP regimen; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: prednisone; Drug: vincristine sulfate; Procedure: conventional surgery; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Leukemia
Interventions: Drug: cyclophosphamide; Drug: cytarabine; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: thioguanine; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Breast Cancer
Intervention: Radiation: radiation therapy
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI); Radiation Therapy Oncology Group; Southwest Oncology Group
Recruiting - verified March 2010
Condition: Leukemia
Interventions: Biological: epratuzumab; Biological: filgrastim; Drug: asparaginase; Drug: cyclophosphamide; Drug: cytarabine; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: leucovorin calcium; Drug: methotrexate; Drug: pegaspargase; Drug: prednisone; Drug: therapeutic hydrocortisone; Drug: vincristine sulfate
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Leukemia
Interventions: Biological: filgrastim; Drug: cyclophosphamide; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: dexamethasone; Drug: etoposide; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: therapeutic hydrocortisone; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Pneumonia, Staphylococcal
Interventions: Drug: linezolid; Drug: vancomycin
Sponsor: Pfizer
Recruiting - verified February 2010
Condition: Brain and Central Nervous System Tumors
Interventions: Drug: cisplatin; Drug: cyclophosphamide; Drug: lomustine; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Cancer
Interventions: Genetic: cytogenetic analysis; Genetic: mutation analysis; Genetic: polymorphism analysis; Other: questionnaire administration
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Metastatic Cancer; Prostate Cancer
Interventions: Drug: zoledronic acid; Other: placebo
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI); Southwest Oncology Group; Eastern Cooperative Oncology Group; NCIC Clinical Trials Group
Recruiting - verified March 2010
Condition: Sarcoma
Interventions: Biological: dactinomycin; Drug: cyclophosphamide; Drug: vincristine sulfate; Procedure: conventional surgery; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Leukemia
Interventions: Drug: cyclophosphamide; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: prednisone; Drug: thioguanine; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Biological: filgrastim; Biological: pegfilgrastim; Biological: trastuzumab; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: paclitaxel
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Drug: exemestane; Drug: tamoxifen citrate; Drug: triptorelin; Procedure: oophorectomy; Radiation: radiation therapy
Sponsors: International Breast Cancer Study Group; National Cancer Institute (NCI); Breast International Group; Cancer and Leukemia Group B; NCIC Clinical Trials Group; North Central Cancer Treatment Group; National Surgical Adjuvant Breast and Bowel Project (NSABP); Southwest Oncology Group
Recruiting - verified March 2010
Condition: HIV Infections
Intervention: Drug: Tipranavir
Sponsor: Boehringer Ingelheim Pharmaceuticals
Available - verified March 2010
Conditions: Childhood Germ Cell Tumor; Extragonadal Germ Cell Tumor; Ovarian Cancer
Interventions: Biological: bleomycin sulfate; Drug: cisplatin; Drug: etoposide; Procedure: conventional surgery
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: paclitaxel
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Enteroviral Sepsis
Interventions: Drug: Placebo; Drug: Pleconaril (VP63843)
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified February 2010
Condition: Neuroblastoma
Interventions: Biological: aldesleukin; Biological: monoclonal antibody Ch14.18; Biological: sargramostim; Drug: isotretinoin
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: HIV Infections
Intervention:
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2009
Condition: Breast Cancer
Interventions: Drug: letrozole; Other: placebo
Sponsors: NCIC Clinical Trials Group; National Cancer Institute (NCI); North Central Cancer Treatment Group; International Breast Cancer Study Group; Eastern Cooperative Oncology Group; Southwest Oncology Group; Cancer and Leukemia Group B; European Organization for Research and Treatment of Cancer
Recruiting - verified June 2009
Condition: Melanoma (Skin)
Interventions: Biological: recombinant interferon alfa; Other: clinical observation
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI); Southwest Oncology Group; Cancer and Leukemia Group B; NCIC Clinical Trials Group; Children's Oncology Group
Recruiting - verified March 2010
All Locations ... United States » ... Tennessee » ... Nashville 
Login/sign up for more tools for finding clinical trials. Login/Sign up Here
